NCT06824051CompletedPhase 1
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 27 Jan 2025
- Start date
- 17 Feb 2025
- Primary completion date
- 26 Jan 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06824051
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 120
- From 17 Feb 2025 to the primary completion date, 26 Jan 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have an unstable body weight within 90 days prior to screening
- Are taking other medications or alternative remedies to manage weight loss
Other illness
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have acute or chronic hepatitis
Who the study is looking for
- Have a Body Mass Index (BMI)
- ≥30.0 kilograms per square meter (kg/m2), or
- ≥27.0 kg/m2 with comorbidities
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio Clinical Trials Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Axis Coordinator of this site? Confirm its status | Dilworth | United States | Unknown status |
| Clinical Pharmacology of Miami Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Endeavor Clinical Trials Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.